Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.12 per share
-
Shares outstanding
-
113,609,919
-
Total 13F shares
-
33,516,836
-
Share change
-
+33,516,836
-
Total reported value
-
$362,234,361
-
Price per share
-
$10.90
-
Number of holders
-
14
-
Value change
-
+$362,234,361
-
Number of buys
-
14
Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) as of Q4 2022
As of 31 Dec 2022,
NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,516,836 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Medicxi Ventures Management (Jersey) Ltd, BVF INC/IL, GMT CAPITAL CORP, JANUS HENDERSON GROUP PLC, and Ensign Peak Advisors, Inc.
This page lists
14
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.